Alkermes plc has grown revenue 4.5% a year over three years and 8.7% a year over five, with earnings per share compounding at −12%. Revenue growth, 3-year annual rate: +4.5% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +8.7%, growth has slowed since the five-year average. Earnings per share, 3-year rate: −12%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 16, FY2009 to FY2025, as filed.

ALKSAlkermes plc

Healthcare

$40.63+46% 1Y

$40.63

$27.1352 weeks$52.99

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +11% year on year, but earnings down −82% year on year and operating margin narrowing (−16.2 points).

1 good, 2 to watch

Revenue trend+11% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.

Earnings trend−82% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−16.2 points operating

Trailing-twelve-month operating margin, 7.3% now against 23.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ALKS growing?

Alkermes plc has grown revenue 4.5% a year over three years and 8.7% a year over five, with earnings per share compounding at −12%.

+4.5%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +8.7%
Revenue growth, 5-year rate · +4.5% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: −12%
Earnings per share, 3-year rate · revenue +4.5% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 16
Years of annual history on file · FY2009 to FY2025, as filed